Krabbe disease is a rare, inherited disorder that destroys the protective coating around nerve cells in the brain and throughout the body. It affects roughly 1 in 250,000 live births, and in its most common form, it strikes infants within the first few months of life. The disease is caused by a missing enzyme, and without that enzyme, a toxic substance builds up and systematically breaks down the insulation nerves need to send signals.
How Krabbe Disease Damages the Nervous System
Every nerve in your body is wrapped in a fatty coating called myelin, which works like insulation on an electrical wire. Myelin allows signals to travel quickly and efficiently between your brain and the rest of your body. In Krabbe disease, the body can’t produce enough of an enzyme that normally breaks down certain fats used in myelin maintenance. Without this enzyme, a toxic byproduct accumulates inside the cells responsible for making and maintaining myelin. That buildup poisons and destroys those cells, stripping nerves of their insulation.
As myelin breaks down, nerve signals slow or stop entirely. This affects everything from movement and muscle tone to vision, hearing, and swallowing. The damage is progressive, meaning it worsens over time, and it occurs in both the brain and the peripheral nerves that run through the arms, legs, and organs.
The Four Types Based on Age of Onset
Krabbe disease is classified into four subtypes depending on when symptoms first appear: early infantile (birth to 5 months), late infantile (6 to 36 months), juvenile (3 to 16 years), and adult onset (older than 16). The early infantile form is by far the most common and most severe, accounting for about 80% of all cases.
Adult-onset Krabbe disease is very rare, making up fewer than 10% of cases, and is likely underdiagnosed. Adults typically present with leg stiffness and weakness, difficulty walking, and slurred speech. Brain imaging in these patients shows a characteristic pattern of white matter damage concentrated in the back of the brain and along the nerve pathways that control movement. Because these symptoms overlap with many other neurological conditions, adult-onset Krabbe can take years to diagnose.
What Early Infantile Krabbe Looks Like
In the early infantile form, babies usually appear healthy at birth. The first signs of trouble tend to emerge around 3 to 5 months of age. In a study of 117 infants, the most common initial symptom was extreme irritability, present in 56% of cases, with a median onset at 4 months. Nearly half showed developmental delay or loss of skills they had already learned, and a similar proportion had feeding or swallowing difficulties and muscle stiffness in the limbs.
The progression is relentless. By 18 to 23 months, 100% of untreated children had swallowing difficulties. Trunk weakness affected about half of infants between 3 and 5 months and reached 100% by 18 months. Staring episodes, which began in about a quarter of infants between 3 and 6 months, increased to 85% by age 2. Seizures appeared as early as 3 to 5 months in some children, rising to 28% by the second year. No untreated child in the study ever walked independently.
The average lifespan for children with infantile Krabbe disease is 13 months, and most die by age 2. The late-onset types carry a somewhat better prognosis, with life expectancy averaging 5 to 7 years after symptoms begin.
How It’s Inherited
Krabbe disease follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty copy of the responsible gene from both parents to develop the disease. If both parents are carriers, each pregnancy carries a 25% chance of producing an affected child. Carriers themselves have no symptoms.
The gene involved provides instructions for making the enzyme that keeps myelin healthy. The single most common mutation, found in about 45% of affected individuals of European ancestry, is a large deletion that removes a significant portion of the gene. The same deletion accounts for roughly 35% of cases in individuals of Mexican heritage. Beyond this deletion, dozens of other mutations have been identified, which partly explains why the disease can range from devastating in infancy to slowly progressive in adulthood.
Diagnosis and Newborn Screening
Krabbe disease is confirmed by measuring enzyme activity in white blood cells or skin cells. Affected patients typically have enzyme levels between 0% and 5% of normal. Levels between 8% and 20% in someone without symptoms are considered inconclusive and require genetic testing to clarify.
Brain imaging plays an important role in assessing how far the disease has progressed. MRI scans reveal white matter damage, and research has shown that even at birth, the nerve pathways controlling movement already look different in affected newborns compared to healthy ones. CT scans can pick up areas of unusually high density in the brain, an early and specific finding in infantile cases. Elevated protein levels in spinal fluid and abnormal responses on hearing and vision tests provide additional evidence.
In 2024, Krabbe disease was added to the federal Recommended Uniform Screening Panel, the official list of conditions that all U.S. states are encouraged to screen for at birth. Several states, including New York and Minnesota, had already begun screening. New York’s program stratifies newborns by enzyme level: those with the lowest activity (0.15 or below) are classified as high risk and monitored closely. A scoring system that combines neurological exams, brain imaging, spinal fluid protein, nerve conduction tests, and genetic results helps determine which children should be referred for treatment.
Treatment With Stem Cell Transplant
The only treatment that can alter the course of Krabbe disease is a stem cell transplant, in which healthy donor cells are introduced to provide the missing enzyme. The critical factor is timing. Transplants performed before symptoms appear produce the best results, with children achieving normal or near-normal development in most areas, though some gross motor delays remain common.
For children transplanted after symptoms have already started, outcomes depend heavily on when those symptoms began. Children whose disease appeared after 12 months of age showed better cognitive outcomes than untreated children. But for those whose symptoms emerged at 12 months or younger, transplant outcomes were comparable to no treatment at all in terms of cognitive function. Across all groups, transplant recipients lived longer and had better functional abilities than untreated patients.
This narrow window is what makes newborn screening so critical. Because the disease progresses rapidly in its infantile form, even a few weeks of delay can mean the difference between a transplant that preserves brain function and one that comes too late to help. For late-onset forms, the slower progression offers more time, but the challenge shifts to getting the right diagnosis in the first place.